Seno Medical

02/11/2025

In addition to featuring Imagio®, the latest Breast Health page at Future of Personal Health includes valuable resources for women on topics like early detection, dealing with a diagnosis, and promising advances in care.Help us increase the visibility of this campaign by sharing this post with your followers. Together, we can keep improving the outcomes for breast cancer.

https://pulse.ly/xms7cnvtvd

02/04/2025

Read about the real life results of Imagio® and the reduced number of false positive biopsies following a worrisome screening mammogram. Imagio® takes center stage in Future of Personal Health’s Breast Health campaign as a technology that has “matured rapidly” in the past five years. Read the full article at https://pulse.ly/lwbjnqocmd

01/30/2025

In addition to being FDA approved, Imagio® was awarded a CPT code last year so physicians, facilities, and other qualified healthcare providers can file reimbursement claims for utilizing opto-acoustic technology to diagnose breast cancer. See our guide to reimbursements at https://pulse.ly/klyz6hpigo

01/28/2025

It’s no secret that radiolgists and breast imaging staff are over-burdened. Is this the year that you turn over a new leaf? Imagio® has demonstrated the impact of reducing false positive biopsies by as much as 75%. Get all of the details on improving practice efficiency in our ebook: https://pulse.ly/rniyiuczzs

01/24/2025

The challenges of diagnosing breast cancer will only keep increasing. It’s an old problem we have to solve in a new way. Imagio® represents the first technology that actually reduces the burden on your clinical staff and provides faster diagnosis to patients. If you are ready for a new way forward, make your resolution to get a demo this year: https://pulse.ly/bgomjt1vho

01/22/2025

A panel of breast health experts discuss the latest advancements in breast cancer detection, including our own board member, Agnes Berzsenyi, who explains how technology like Imagio® are improving the patient experience.
“With OA imaging, more patients will receive an “all clear” result, avoiding unnecessary follow-up exams.” – Agnes Berzsenyi
Read the interviews at https://pulse.ly/iyzpjguk5q which were released this month on USA TODAY.

Our panel of experts shares the latest advancements in breast cancer detection and treatment that are empowering all women.

01/20/2025

Can you really add more patients with your existing resources? When breast imaging centers need to improve efficiency, the solution may be simpler than you think. Imagio® reverses the ratio of negative biopsies, so you can focus on more patients and fewer follow-up diagnostic visits. Learn more about improving practice efficiency at: https://pulse.ly/vix0mfgrzs

01/17/2025

What if there was a way to avoid biopsies and detect breast cancer in a faster, more cost-effective way?
Read the full write-up on Imagio® in The Future of Personal Health, a breast health awareness campaign featured this month in USA TODAY. https://pulse.ly/j031u4dwxv

Nearly half of patients screened for breast cancer need two follow-up diagnostic exams. About 20% have three follow-up appointments, and about 10% have four. Meanwhile, 1 in 10 women who undergo these exams receive a biopsy, an often uncomfortable and stressful procedure that involves removing a sma...

01/09/2025

An analysis in the Annals of Internal Medicine discovered how many women skip future screening after false negative results. Imagio® directly addresses this problem by reducing negative exams in the follow-up to a suspicious mammogram. https://pulse.ly/rxbzgmgikp

Reference: Diana L. Miglioretti, Linn Abraham, Brian L. Sprague, et al. Association Between False-Positive Results and Return to Screening Mammography in the Breast Cancer Surveillance Consortium Cohort. Ann Intern Med.2024;177:1297-1307. [Epub 3 September 2024]. doi:10.7326/M24-0123

01/07/2025

One of the primary factors that reduces participation in breast screening is simply access to care and transportation, especially in underserved and rural communities. Requiring multiple diagnostic tests only exacerbates the burden on patients. Imagio® reduces the need for multiple diagnostic visits by providing more diagnostic confidence at the initial point of care. https://pulse.ly/tx9guvijrl


Reference: Castaldi, M., Smiley, A., Kechejian, K. et al. Disparate access to breast cancer screening and treatment. BMC Women's Health 22, 249 (2022). [doi.org/10.1186/s12905-022-01793-z](doi.org/10.1186/s12905-022-01793-z "/linkBuilder_4yGunGFhMtxtDQnL6BCM7j")

12/31/2024

Before we wrap up this beautiful season, we want to wish all of you a Happy New Year. There is much to come with new installations and our partnership with Vizient. We look forward to helping imaging centers realize the benefits Imagio® can bring in 2025, especially to patients. https://pulse.ly/g6qvqfjofn

12/23/2024

Happy Holidays from all of us at Seno Medical. We are so grateful to our customers, advocates, and team involved in bringing Imagio® to imaging centers across the US. We look forward to our continued partnerships and work in advancing the future of breast cancer diagnostics – and helping patients receive the care they need. https://pulse.ly/tbjwi0v0jp